-
After Second Look Oncopeptides' Melflufen Wins Head-To-Head Myeloma Trial, But Difference In OS Triggers FDA Hold
Thursday, July 8, 2021 - 10:00am | 287Oncopeptides AB (OTC: ONPPF) has some good news and some bad news from the updated results from Phase 3 OCEAN study of Pepaxto (melflufen) plus dexamethasone in patients with relapsed / refractory multiple myeloma who have received 2 – 4 prior lines of therapy. The good news...
-
Goldman: Bluebird Bio Is One Step Closer To A Sickle Cell Cure
Monday, December 11, 2017 - 1:42pm | 429Bluebird bio Inc (NASDAQ: BLUE)'s multiple myeloma therapy coud have a "disruptive impact" on treatment of the disease, according to Goldman Sachs. The Analyst Goldman Sachs' Salveen Richter maintains a Buy rating on bluebird's stock and raised the price target from $186 to...
-
Analyst Breaks Down Bluebird Bio's Better-Than-Expected Clinical Results
Thursday, December 1, 2016 - 2:33pm | 371Wedbush analyst David Nierengarten maintains his Outperform rating and $95 target price on bluebird bio Inc (NASDAQ: BLUE), which announced positive results from its early-stage cancer study. Cambridge, Massachusetts-based bluebird bio said early data from its ongoing Phase 1 study of bb2121 showed...
-
Bluebird's Encouraging Myeloma Data Not Enough For Cantor To Lift Its Sell Rating
Thursday, December 1, 2016 - 8:59am | 299Bluebird bio Inc (NASDAQ: BLUE) announced positive early data from its ongoing open-label Phase 1 CRB-401 study with its CAR T candidate, bb2121, in patients with relapsed and/or refractory multiple myeloma. Although the initial early data is encouraging, there are potential risk of CRS [...
-
Cellectar Biosciences Spiked 30% On Phase 2 INC Contract
Tuesday, November 15, 2016 - 2:28pm | 302Cellectar Biosciences Inc (NASDAQ: CLRB), a nano-cap oncology-focused clinical-stage company, announced on Tuesday a new collaboration to better explore a phase 2 clinical trial. Cellectar selected INC Research Holdings Inc (NASDAQ: INCR), a leading contract research organization, to oversee...
-
Amgen's Kyprolis Fails To Met Endpoint, But It's Not All Bad News
Wednesday, September 28, 2016 - 10:02am | 364Amgen, Inc. (NASDAQ: AMGN) announced that the Phase 3 CLARION trial for Kyprolis in first-line multiple myeloma (MM) did not meet the primary endpoint. Goldman Sachs’ Terence Flynn maintains a Buy rating on the company, while lowering the price target from $206 to $198. Disappointing Data...